The Most Expensive Prescribers in Medicare Part D

Not all prescribers cost the same. Among 1,380,665 Medicare Part D providers, a small number generate vastly disproportionate drug spending. But high cost doesn't necessarily mean bad practice — an oncologist prescribing life-saving cancer drugs will always cost more than a family doctor writing prescriptions for blood pressure medication. The question is: which high-cost prescribers are justified, and which warrant scrutiny?

The Top 25 Most Expensive Prescribers

These are the providers who generated the most drug spending in Medicare Part D. The list reveals a mix of specialties, practice sizes, and geographic locations:

Which Specialties Dominate?

The specialty distribution of top-cost prescribers tells an important story about where Medicare drug dollars actually flow:

Justified vs. Questionable High Cost

Context matters enormously when evaluating prescriber cost. Some specialties should generate high drug costs:

Geographic Distribution

Where are the most expensive prescribers located? The state distribution of the top 100 reveals concentration in large population states, but some smaller states are overrepresented:

Cost Per Beneficiary: The Real Measure

Total cost alone is misleading. A provider seeing 500 patients who generates $80K in drug costs is different from one seeing 10 patients who generates the same. Cost per beneficiary normalizes for patient volume and reveals which providers are prescribing the most expensive drugs per person:

The national average cost per beneficiary is roughly $1,250. Providers at 10x or more above this average are worth investigating — though specialty context is essential.

Risk Flags Among Top Prescribers

Of the top 100 most expensive prescribers, 67 have at least one risk flag in our scoring system. The flags found include:

The Brand Name Premium

Among the top 100 most expensive prescribers, the average brand-name prescription rate is 29.2% (vs. the national average of 13.4%). Some of the highest-cost providers prescribe brands at extraordinarily high rates:

What This Means for Medicare

The concentration of drug costs among a relatively small number of prescribers has important policy implications:

• Targeted oversight — Monitoring the top 1% of prescribers by cost could capture a disproportionate share of wasteful spending
• Specialty-adjusted benchmarks — Comparing prescribers to their peers within the same specialty is more meaningful than raw cost rankings
• Biosimilar adoption — High-cost prescribers in oncology and rheumatology who aren't using available biosimilars represent a significant savings opportunity
• Prior authorization — While burdensome, prior auth for the most expensive drugs can redirect spending when cheaper alternatives exist

Explore Related Analysis

• The $160 Million Prescriber — Medicare's Most Expensive Doctor
• Who Are the Highest-Cost Prescribers?
• Which Specialties Drive the Most Spending?
• PBMs: The Middlemen Driving Drug Costs
• Brand vs Generic: The Prescribing Gap
• How We Score Prescribing Risk